Understanding how certain proteins contribute to ovarian cancer's resistance to platinum treatment
Novel protein kinase signaling associated with platinum resistance in ovarian cancer
This study is looking at why some ovarian cancer patients don't respond well to platinum-based treatments, focusing on a protein called SRMS that might be key in this resistance, especially for those with certain tumor types, to help find better ways to treat the cancer and improve outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10926934 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms that lead to platinum resistance in ovarian cancer, which is a significant factor in cancer recurrence and mortality. The team has identified a specific protein, SRMS, that appears to play a crucial role in this resistance, particularly in patients with p53-deficient tumors. By analyzing cancer cell lines and patient data, the researchers aim to understand how SRMS affects the cancer cells' response to platinum-based therapies and the associated signaling pathways involved in cell death. This could lead to new strategies for overcoming resistance and improving treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are ovarian cancer patients, particularly those with p53-deficient tumors who have experienced resistance to platinum-based therapies.
Not a fit: Patients with p53-competent tumors or those who have not undergone platinum-based treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer patients who currently struggle with platinum resistance.
How similar studies have performed: Other research has shown promising results in targeting similar molecular pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Huang, Shuang — University of Florida
- Study coordinator: Huang, Shuang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.